Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2010 - 2026)

Regeneron Pharmaceuticals has reported Accumulated Expenses for 13 years, with the latest figure at $2.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 21.53% year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 21.53% YoY), and the FY2025 full-year result was $2.9 billion, up 13.82% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.7 billion, down from $2.9 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $3.0 billion in Q3 2025, with the low at $1.8 billion in Q3 2022.
• Average Accumulated Expenses over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2024.
• Year-over-year, Accumulated Expenses dropped 12.84% in 2022 and soared 47.22% in 2023.
• Tracing REGN's Accumulated Expenses over 5 years: stood at $2.1 billion in 2022, then grew by 13.68% to $2.4 billion in 2023, then grew by 7.18% to $2.5 billion in 2024, then climbed by 13.82% to $2.9 billion in 2025, then declined by 5.28% to $2.7 billion in 2026.
• The last three Accumulated Expenses figures came in at $2.7 billion (Q1 2026), $2.9 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.

Peer Comparison